Paul I. Chang M.d.
Executive member
Management
Janssen
Portugal
Biography
Mr. Paul I. Chang, M.D. serves as Vice President of Medical Affairs for Internal Medicine at Janssen Pharmaceuticals, Inc. Mr. Chang has been Vice President of Worldwide Clinical Research & Operations at Cordis Corporation since October 2008. Dr. Chang is responsible for clinical development strategy, clinical trial execution, and the Program Management Office (PMO) at Cordis. He joined Johnson & Johnson Pharmaceutical Research and Development (J&J PRD) in 2006 as Therapeutic Area Head of Cardiovascular and served as its Head of Internal Medicine. He has over a 12 of experience leading pharmaceutical, biologic, and drug-device combination development projects. Dr. Chang served as Chief Medical Officer and Vice President of Regulatory Affairs and Clinical Development of Tengion Inc. since September 2005. Dr. Chang served as Vice President of Cardiovascular and Immunology Global Clinical Research at Bristol Myers Squibb Co. Over the past decade, he has formulated clinical development plans and regulatory strategies for over 10 compounds in late stage development, and completed multiple successful NDA and BLA filings. Dr. Chang has been a leader and mentor to large teams of colleagues from areas of clinical research, development operations, and regulatory affairs. Dr. Chang held leadership positions in Cardiovascular Clinical Research at Merck & Co. Dr. Chang holds a BA degree in Biochemistry from Columbia University, an M.D. degree from Yale University School of Medicine and Internal Medicine residency from Cornell University-the New York Hospital. Dr. Chang holds Cardiovascular Medicine fellowship from Yale University.
Research Interest
Cardiovascular medicine
